{
  "data": {
    "financials": {
      "sales_growth_3yr_avg": 13.9,
      "profit_growth_3yr_avg": 48.8,
      "roe_latest": 16.9,
      "roce_latest": 20.2,
      "pe_ratio": 36.1,
      "debt_to_equity": 0.07,
      "beta": 0.51
    },
    "dcf_inputs": {
      "free_cash_flow_latest_cr": 8734,
      "growth_rate_projection": 14.0,
      "shares_outstanding_cr": 240,
      "net_debt_cr": -22665,
      "tax_rate": 25.0
    },
    "qualitative": {
      "management_integrity_score": 6,
      "reasoning": "Sun Pharma is a global leader with a strong promoter holding (54.5%), but its governance score is impacted by historical whistleblower complaints and recent regulatory penalties (Nov 2024) imposed on directors regarding related party transaction disclosures. While operations are robust, these governance lapses weigh on the integrity score."
    }
  },
  "_cached_at": "2025-12-24T22:05:57.434794",
  "_symbol": "SUNPHARMA"
}